PNPLA3 and metabolic dysfunction-associated steatohepatitis: A phase 1 study currently recruits patients with NASH and the PNPLA3 rs738409 variant to investigate the safety and tolerability of AZD2693, a drug which structure and role have not been disclosed (NCT04483947).